Stop TB Partnership Indonesia

What Stop TB Partnership Indonesia does

Stop TB Partnership Indonesia (STPI), formally Yayasan Kemitraan Strategis Tuberkulosis Indonesia, is an Indonesian non-profit foundation established in 2018 from the earlier Forum Stop TB Partnership Indonesia (FSTPI, 2013). It operates as a multi-stakeholder partnership hub that convenes government, civil society, private sector, and patient organizations to advance tuberculosis elimination across Indonesia's 34 provinces, addressing a disease burden where the country ranks second globally with an estimated 1,092,000 cases in 2024. STPI's work spans TB policy advocacy (including support for Perpres No. 67 on TB Control), cross-sector governance of the national TB program, public awareness campaigns (Caraka TB Institute, TB Ambassador Program, Journalist TB Fellowship Programme), and direct service delivery.

Its core operational program is the Life-saving Facility and Community-based Service Delivery Support for Tuberculosis (FCSDS), launched in 2026 with US Government funding and deployed in West Java and East Java. FCSDS combines AI-based portable X-ray active case finding, contact investigation, community outreach, drug-resistant TB (TB-RO) treatment support, nutritional and psychosocial services, and Tuberculosis Preventive Therapy (TPT) provision. STPI also operates digital health systems: the MESO (Monitoring Efek Samping Obat) WhatsApp Business API chatbot with AI/NLP for adverse drug reaction reporting from DR-TB patients, the SKAT (Sistem Konektivitas Alat Tes Cepat Molekuler) connectivity platform for molecular diagnostic equipment, and the TB Policy Tracker Indonesia portal. Earlier programs include the TB Alert Village (Desa Siaga TB) initiative in Sumenep and West Lombok and the ADVANCE-TB program.

STPI's revenue model is entirely grant-based, with no commercial pricing. It has received funding from Sanofi (first donor, 2019, TPT campaigns), CFCS (2020, TB patient organization capacity building), the Global Fund via the Penabulu-STPI Consortium (2020), and the US Government (FCSDS, 2026). Services are delivered free of charge to TB patients, healthcare facilities, and civil society partners. The organization is governed by a Board of Trustees chaired by Yaser Raimi Panigoro (with strong Medco Energy lineage), advised by global health experts including Prof. Tjandra Yoga Aditama, and led operationally by Foundation Chair dr. Donald Pardede and Executive Director dr. Henry Diatmo. Total annual revenue is not publicly disclosed.

Name

Stop TB Partnership Indonesia

Legal name

Yayasan Kemitraan Strategis Tuberkulosis Indonesia

Website

https://stoptbindonesia.org

Company type

Private

Founded year

2018

Operating status

Operating

Headcount range

11–50 employees

Short description

Stop TB Partnership Indonesia is a Jakarta-based non-profit foundation that convenes government, civil society, and private-sector partners across Indonesia's 34 provinces to eliminate tuberculosis, delivering AI-based active case finding, drug-resistant TB support, digital health platforms, and policy advocacy funded entirely by international grants.

Ownership category

akta.pro rank

Product category

Public Health Non-Profit Services

NAICS

Social Advocacy Organizations (8133)

akta.pro industry

PRIMARYBPAIAJAH

Communicable Disease Control Programs (TB, HIV/STIs, Hepatitis)

Business & Public Services/Public Sector & Government Administration/Public Health Administration & Regulation

SECONDARYHLAJAOAE

Disease-Specific Global Initiatives (HIV/TB/Malaria/NTDs)

Healthcare & Life Sciences/Public Health, Government & Regulators/Global Health Initiatives & Partnerships

SECONDARYHLAJAOAD

Public–Private Partnerships (PPPs) for Global Health

Healthcare & Life Sciences/Public Health, Government & Regulators/Global Health Initiatives & Partnerships

SECONDARYHLAJANAO

Public Health Reporting, Dashboards & KPI Performance Management

Healthcare & Life Sciences/Public Health, Government & Regulators/Health Program Evaluation & Surveillance

Keywords

• Tuberculosis control programs
• TB policy advocacy
• Community health services
• Digital health platforms
• Public health partnerships

Headquarters

HQ city

Jakarta Selatan, DKI Jakarta

HQ country

Indonesia

HQ region

Asia

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Technology or R&D

Revenue model

1. International Development/Funding Grants: STPI receives funding from international donors for TB control programs. Primary funding includes US government (USAID) funding for the FCSDS (Life-saving Facility and Community-based Service Delivery Support) Project. Also receives support from Global Fund through consortium arrangements.
2. Corporate and Foundation Donations: First donor was Sanofi for TPT drug campaign activities. Also manages donor funds from CFCS for TB POP capacity building.
3. Resource Mobilization and Partnerships: STPI mobilizes resources from various sources including government, civil society, and private sector to support TB elimination efforts in Indonesia.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels5 records

Core offering

Stop TB Partnership Indonesia (STPI) is a non-profit foundation that delivers tuberculosis elimination programs across Indonesia. Its core work spans active case finding using AI-based portable X-ray screening in high-burden districts, digital adverse drug reaction reporting through the MESO WhatsApp chatbot, policy advocacy, cross-sector governance, public awareness campaigns, and resource mobilization from international donors.

Product overview

Stop TB Partnership Indonesia operates as a collaborative organization offering multiple interconnected TB-related programs and digital systems. The core offering includes the FCSDS program with AI-based X-ray screening for active case finding, supported by information systems like the MESO drug side effect reporting system and TB Policy Tracker. The product portfolio also includes the SKAT connectivity system for molecular test equipment and a TB Education platform. These offerings work together to strengthen Indonesia's TB response through policy advocacy, community-based service delivery, and digital health solutions.

Differentiator

Problem solved

Functional benefit

Brands

• FCSDS: Life-saving Facility and Community-based Service Delivery Support for Tuberculosis — a program focused on active case finding with AI-based X-ray screening and strengthening management of drug-resistant TB treatment, expanding TB services in West Java and East Java.
• Caraka TB Institute
• TB Fellowship Programme
• Desa Siaga TB

Products and services

• FCSDS (Life-saving Facility and Community-based Service Delivery Support for Tuberculosis) Comprehensive TB service delivery program expanding reach in West and East Java through active case finding with AI-based X-ray screening, contact investigation, community outreach, and strengthening management of drug-resistant TB treatment including nutritional and psychosocial support for TB-RO patients.
• MESO (Monitoring Efek Samping Obat) Information System Drug side effect reporting information system for drug-resistant TB patients, featuring WhatsApp chatbot for automated complaint collection, online consultation between patients and doctors, and integration with Technical Working Group for case escalation.
• TB Policy Tracker Indonesia Online portal for tracking tuberculosis-related policies in Indonesia, providing access to policy documents and monitoring policy developments.
• SKAT (Sistem Konektivitas Alat Tes Cepat Molekuler) Connectivity System Full stack development services for connectivity system of tuberculosis rapid molecular test equipment, enabling data integration and reporting from molecular diagnostic devices.
• TB Education Platform Educational resources providing reliable information on tuberculosis including symptoms, prevention, treatment and care, empowering individuals and communities to take informed action against TB.

Quantifiable outcome

• Active case finding through AI-based portable X-ray screening in West Java and East Java
• +2 more outcomes

Named customers4 records

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration4 records

AI capability4 records

Feature3 records

Partnerships

Three partnerships are on record, tiered core and flagship.

• BEBAS TB ConsortiumcoreStrategic or Co-development Partner · 1 January 2023STPI joined the BEBAS TB (Bersama Eliminasi TB) Consortium in 2023 for national advocacy to support Public Private Mix (PPM) in TB control.
• Government of Indonesia (Ministry of Health)flagshipStrategic or Co-development Partner · 1 January 2021STPI collaborates with the Ministry of Health on multiple initiatives including organizing the 1st High Level Meeting on TB with President Joko Widodo, and policy advocacy for TB control. STPI is a key partner in the national TB response.
• United Nations (UN HLM TB)flagshipStrategic or Co-development Partner · 1 January 2018STPI collaborated with the Indonesian government for 2 side events at the UN High Level Meeting on Tuberculosis in 2018, contributing to global TB advocacy efforts.

Scale indicators5 records

Recent moves8 records

Expansion highlights5 records

Direct peers

• Partners in Health: Global health NGO focused on delivering healthcare for poverty-associated diseases including drug-resistant TB in low-resource settings. Comparable in operating model of community-based TB service delivery, advocacy, and government partnership in high-burden countries.
• TB Alliance: Global product development partnership working to develop and introduce better TB treatments including BPaL/BPaLM regimens. Comparable to STPI's work socializing BPaL/BPaLM in Indonesia and its role as a multi-stakeholder TB partnership.
• KNCV Tuberculosis Foundation: Dutch-based TB organization with deep expertise in TB program implementation, DR-TB management, and digital health tools for TB. Highly comparable to STPI in mission, programmatic focus on drug-resistant TB, and international donor-funded operating model.

Broad incumbents

• FHI 360: Large international NGO with significant Indonesia TB and health systems portfolio, particularly in HIV/TB integration. Comparable to STPI in operating donor-funded programs, working with civil society, and implementing USAID-funded TB activities in Indonesia.
• PATH: Global health innovation organization with significant TB portfolio across multiple high-burden countries. Comparable to STPI in operating digital health tools, AI-based screening, and cross-sector partnership models for TB and related disease programs.
• Global Fund to Fight AIDS, Tuberculosis and Malaria: Major international financing institution for TB programs. STPI acts as a Principal Recipient of Global Fund grants through the Penabulu-STPI Consortium, making Global Fund both a peer funder and a comparable global health partnership institution.
• Stop TB Partnership (Global): The global parent partnership organization headquartered in Geneva that houses Indonesia's country-level partnership. Directly comparable as both operate under the same TB-elimination mission and brand, with the global body providing technical and policy frameworks that STPI implements locally.
• WHO Global TB Programme: The World Health Organization's technical and policy lead for global TB response. Comparable to STPI as both set TB policy frameworks, with STPI operating as an in-country implementation partner aligned to WHO strategy.

Regional players

• Clinton Health Access Initiative (CHAI): Global health organization with active Indonesia country presence working on TB, HIV, and health systems strengthening. Comparable to STPI in its Indonesia-focused donor-funded programs, government engagement, and market-shaping activities in TB commodities.
• Pekanbaru TB Care Community (or other Indonesian civil society TB peers): Local Indonesian TB-focused civil society organizations delivering community-based TB services. Comparable as direct peers operating in the same geographic and disease-specific context, often competing for the same limited pool of donor funding for community TB activities in Indonesia.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/stop-tb-partnership-indonesia

Revenue estimate

Valuation estimate

Number of profiles

Profiles13 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Stop TB Partnership Indonesia